Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn. The post Insurers are Pulling Back on MA. How Does this Affect Patients? appeared first on MedCity News.
Matthew Thompson, M.D., of Telescope Health, explains his organization’s unique model
If you rely on federal grants as your sole means of support, you’re tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster. The post Will the Entire…
Nearly a year after the Biden administration gave Florida the green light to become the first state to import lower-cost prescription drugs from Canada — a longtime goal of politicians across the political spectrum, including President-elect Donald Trump — the program has yet to begin. Florida Gov. Ron DeSantis hailed the FDA’s approval of his…
Collection agents for the state of Iowa have sent letters seeking millions of dollars from the estates of at least two people with disabilities who died after spending most of their lives in a state institution. The amounts represent what Medicaid spent covering the residents’ care when they lived at the Glenwood Resource Center, a…
For people whose autumn agenda includes getting vaccinated against respiratory diseases — covid, flu, and, for some, RSV — this year may be surprisingly routine. Following several confusing months this summer when federal officials announced and then retreated from changes to covid vaccine recommendations, the Centers for Disease Control and Prevention on Oct. 6 announced…
By MATTHEW HOLT The Democratic convention wrapped with a fine speech from Kamala Harris, star power from the Obamas and Clintons, and a bunch of Republicans telling their ideological brethren that it was better to be a Democrat than a Trumper. More importantly no Beyonce/Taylor Swift duet–as we were promised by Mitt Romney. There was…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
This volume shares findings from the latest KFF Tracking Poll on Health Information and Trust, along with updates from Robert Kennedy Jr’s senate hearings. It also examines distrust in public health messaging about bird flu, motivations for sharing information online, and how fraudulent research can sometimes inform AI chatbot models.
AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics. The post AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test appeared first on…